Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine–Glycine–Aspartate) Strategies
Bojana Bogdanović, Daniel Fagret, Catherine Ghezzi, Christopher Montemagno, Guillermina Ferro-Flores · 2024
Read Integrin Targeting and Beyond: Enhancing Cancer Treatment with Dual-Targeting RGD (Arginine–Glycine–Aspartate) Strategies by Bojana Bogdanović, Daniel Fagret, Catherine Ghezzi, Christopher Montemagno, Guillermina Ferro-Flores (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11597078.txt.
Description
Four researchers review dual targeting cancer drugs built on a short protein tag in a 2024 paper. The tag, known by its three letter code RGD, homes to integrins, grip proteins that help tumors grow, spread, and sprout blood vessels. Drugs built on the tag can scan or treat tumors.
Past agents hit limits: target levels vary, and the body clears the drugs too fast. The review covers fresh designs that aim at two targets at once to sharpen the hit. New agents pair the tag with a second homing part or a stronger payload. The authors argue the dual route can lift both diagnosis and therapy.
Catalog record
| CREATOR | Bojana Bogdanović, Daniel Fagret, Catherine Ghezzi, Christopher Montemagno, Guillermina Ferro-Flores |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |